Please login to the form below

Not currently logged in
Email:
Password:

Arcus Biosciences

This page shows the latest Arcus Biosciences news and features for those working in and with pharma, biotech and healthcare.

Gilead agrees $21bn buyout of Immunomedics

Gilead agrees $21bn buyout of Immunomedics

In May, Gilead also announced its intent to partner with Arcus Biosciences on the development and commercialisation of next-generation cancer immunotherapies. ... This included gaining rights to zimberelimab, an investigational anti-PD-1 monoclonal

Latest news

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Acquisition. $463m. Precision BioSciences/. Gilead Sciences. ARCUS technology; targeting in vivo elimination of. ... Gilead has also agreed a strategic collaboration with Precision BioSciences worth $445m in potential milestones; in addition there are

  • Pharma deals continue to slide Pharma deals continue to slide

    Arcus, a privately owned US immuno-oncology company, may have to do the same following its deal to license a monoclonal antibody from the Chinese companies WuXi Biologics and Gloria Pharmaceuticals. ... 1, 410 (upfront 80). WuXi Biologics and Gloria

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

Ask the writers: Transitioning from academia to medical writing
Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
Strategic launch planning: familiar framework, new mindset
By James Aird...
Guide
How to embrace behavioural science principles in healthcare MR...